View original post 15,725 more words
(biotinylated idraparinux, SSR-126517, SSR-126517E)
405159-59-3 9 x Na salt
774531-07-6 (free acid)
Idrabiotaparinux has an attached biotin moiety at the non-reducing end unit, which allows its neutralisation with avidin, an egg-derived protein with low antigenicity. This compound is currently investigated in clinical trials for prevention of recurrent VTE in patients with acute pulmonary embolism. The future of idrabiotaparinux depends also on the safety and efficacy of avidin.
Symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE) – treatment and secondary prevention of recurrent venous thromboembolism (VTE).
SSR-126517, a biotinylated idraparinux, had been in phase III clinical trials at Sanofi (formerly known as sanofi-aventis) for the treatment of pulmonary embolism, deep venous thrombosis (DVT) and atrial fibrillation. However, in 2009, development of the compound was discontinued.
Idrabiotaparinux (biotinylated idraparinux, SSR-126517, SSR-126517E) is a long-acting selective pentasaccharide indirect factor Xa coagulation inhibitor, administered by…
View original post 4,397 more words